Ryzneuta is a novel dimeric G- CSF long-acting fusion protein without pegylation. The Biologics License Application (BLA) of Ryzneuta is currently under late-stage review by the US FDA for Chemotherapy-Induced Neutropenia (CIN)
The company offers a wide portfolio of services including integrated doctor-led prescription e-commerce enablement, digital health record management, and smart clinics.
The show will be a part of the India Pharma Week, a marquee celebration catering to every need of the pharma community attendees
The company registered with REACH Certificate for Ethyl Acetate with a tonnage band of more than 1000 TPA
The core of “LANXESS Biosecurity Solutions” is a portfolio of scientifically formulated, highly effective and versatile biocidal products
Value chain collaboration aims to foster a circular ecosystem and reduce the carbon footprint of single-use surgical instruments molded in Ixef PARA.
Revenue is up 23% whereas Profit After Tax expands 29% for the company
Innovative Capsugel Enprotect capsule can simplify the manufacturing process to accelerate drug development and expedite first-in-human timelines
NFIL’s ambition is to reach revenues of US$100mn from CDMO by FY25.
Subscribe To Our Newsletter & Stay Updated
